A crossover trial of bromocriptine in the treatment of vascular dementia.
Seven patients with vascular dementia completed an 8-month randomized double-blind crossover trial of bromocriptine in a dosage of up to 30 mg per day. Patients were assessed using a modified UCLA Parkinson Rating Scale of symptoms and signs, and neuropsychological testing including the Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale, modified Thurstone Word Fluency Test, Wisconsin Card Sort, a test of visual vigilance, and a reaction time task. Subjects failed to perform significantly better on any measure while on bromocriptine, and on several measures their performance while on the drug was worse.
D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests
D001971:Bromocriptine